Migalastat Hydrochloride
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB05018 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 14 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | hepatopulmonary syndrome | KG + DL |
| 2 | primitive portal vein thrombosis | KG + DL |
| 3 | early-onset familial noncirrhotic portal hypertension | KG + DL |
| 4 | hepatoportal sclerosis | KG + DL |
| 5 | idiopathic copper-associated cirrhosis | KG + DL |
| 6 | hepatic porphyria | KG + DL |
| 7 | mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies | KG + DL |
| 8 | disorder of tyrosine metabolism | KG + DL |
| 9 | teratogenic Pierre Robin syndrome | KG + DL |
| 10 | nodular regenerative hyperplasia of the liver | KG + DL |
| 11 | tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuria | KG + DL |
| 12 | exocrine pancreatic insufficiency | KG + DL |
| 13 | disorder of phenylalanine metabolism | KG + DL |
| 14 | pyelonephritis | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.